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Figure 1. Upper left, Photograph showing skin lesions on arm and shoulder of patient. Upper right, CT scan of neck revealing multiple enlarged
lymph nodes. Lower left, Detail of a skin ulcer on forehead of patient. Lower right, Histologic examination of skin biopsy specimen showing perivascular
infiltrates of neutrophil granulocytes and ovoid yeasts (diameter, 15 mm) and a thick cell wall (periodic acid–Schiff stain; original magnification,400).
Diagnosis: Disseminated African histoplasmosis in an Afri-
can patient with AIDS.
The disease process included skin eruptions, bone lesions,
and hematologic and multiple-organ involvement, and the
cause was Histoplasma capsulatum var. duboisii.
H. capsulatum var. duboisii, the causative agent of African
histoplasmosis, is a thermally dimorphic fungus that grows in
mold form at 25C and in yeast form at 37C. Compared with
H. capsulatum var. capsulatum, H. capsulatum var. duboisii is
much larger (12–15 vs. 2–4 mm) and has a thicker wall, although
mycelial forms are indistinguishable. African histoplasmosis is
endemic in Central and West Africa south of the Sahara and
north of the Zambezi River. As a result of intensification of
travel and immigration, the number of cases of African his-
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toplasmosis is likely to increase in industrialized countries in
the future. The natural habitat is soil contaminated with bird
droppings or bat excrement. It is thought that H. capsulatum
var. duboisii enters the body through the lungs, although pri-
mary pulmonary infection has not been demonstrated. Al-
though cutaneous inoculation is an alternative mode of ac-
quisition, human-to-human transmission is not a significant
route of infection transmission.
Patients usually present with focal disease affecting the skin,
subcutaneous tissue, and bone, leading to skin ulcers or nod-
ules, subcutaneous tender nodules, and osteolytic bone lesions
(mainly in the skull, ribs, and vertebrae). A rare case of in-
volvement of the gastrointestinal tract that mimics gastroin-
testinal cancer has also been reported [1]. In addition, a rapidly
progressive systemic dissemination with multiple-organ in-
volvement (including liver, spleen, lung, and kidney) is possible.
There is no clear correlation between host immune status and
infection with H. capsulatum var. duboisii [2].
Diagnosis chiefly relies on demonstration of the quite char-
acteristic large, oval yeasts seen on direct microscopic exami-
nation of tissue biopsy specimens (figure 1, lower right). Con-
firmation by culture is possible, but difficult, because the long
generation time (6 to 130 h, depending on medium and in-
oculum) allows for growth of saprophytic fungi and bacteria.
Antigen testing of blood or urine specimens has adequate
sensitivity only for disseminated disease, which is quite rare in
patients with African histoplasmosis. The results of serologic
tests are generally negative [3], because cross-reaction may oc-
cur with Blastomyces species and Coccidioides immitis. The his-
toplasmin skin test is of epidemiological interest only. Most
patients with a positive reaction to H. capsulatum var. duboisii
antigen also react positively to H. capsulatum var. capsulatum
antigen, and vice versa.
The standard treatment for H. capsulatum var. duboisii in-
fection is amphotericin B at a dosage of 1 mg/kg per day, with
a minimum cumulative dose of 2 g [4, 5]. Itraconazole and
ketaconazole are alternatives mainly for the nondisseminated
form of disease or for use after induction therapy with am-
photericin B. Fluconazole is less active than itraconazole against
H. capsulatum infection [6, 7]; moreover, resistance to flucon-
azole may develop [8]. Caspofungin has little activity in vivo
[9]. Prolonged treatment (6 months) is mandatory to de-
crease the risk of relapse. Our patient received systemic am-
photericin B (1 mg/kg of body weight) for 2 weeks, followed
by itraconazole (400 mg per day for 10 weeks, then 200 mg
per day) maintenance therapy, which is also used for the classic
form of histoplasmosis.
Prognosis of focal disease is affected by relapses that occur
up to several years after antifungal therapy has been stopped,
which makes the term “remission” more accurate than “cure,”
unless data from prolonged follow-up are available. The out-
come for disseminated African histoplasmosis in HIV-positive
patients has been poor thus far [10]. Our experience demon-
strates that, even in these cases, remission is possible, if early
diagnosis is followed by adequate antimycotic therapy.
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